Press releases
- EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress
- ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
- AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
- Ascentage Pharma Announces 2023 Annual Results
- AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
More ▼
Key statistics
On Thursday, Ascentage Pharma Group International (36X:FRA) closed at 2.40, 29.03% above the 52 week low of 1.86 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.42 |
---|---|
High | 2.42 |
Low | 2.40 |
Bid | -- |
Offer | -- |
Previous close | 2.44 |
Average volume | 351.20 |
---|---|
Shares outstanding | 290.22m |
Free float | 212.89m |
P/E (TTM) | -- |
Market cap | 5.96bn HKD |
EPS (TTM) | -3.53 HKD |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼